Experimental drug SHR-A1904 takes on rare cancer
NCT ID NCT07520357
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests an experimental drug called SHR-A1904 in 23 people with advanced neuroendocrine carcinoma whose cancer has worsened after standard chemotherapy. The study measures how many patients have their tumors shrink or disappear, how long they live without the cancer growing, and overall survival. It is a single-center, prospective study that will also track side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-A1904 (an experimental drug given by injection)
- What this could lead to
- If successful, this could provide a new treatment option for people with advanced neuroendocrine carcinoma who have not responded to standard chemotherapy.
- What could go wrong
- This is a small, early-phase trial with only 23 participants, so results may not apply to everyone. The drug may cause side effects and might not shrink tumors or extend survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NEUROENDOCRINE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing GoBroad Hospital
Beijing, Beijing Municipality, 100142, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.